Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Ripretinib (Qinlock) - To treat advanced gastrointestinal-stromal tumors Drug Approval Package: QINLOCK U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: QINLOCK Company: Deciphera Pharmaceuticals, LLC Application Number: 213973 Approval Date: 05/15/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF
Is 45 really the new 50 in colorectalcancer screening? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca June 29, 2020 (...) Is 45 really the new 50 in colorectalcancer screening? Clinical Question: Should we lower the age that average risk patients commence colorectalcancer screening from 50 to 45? Bottom Line: In developed countries, the incidence of colorectalcancer in persons under 50 years old has increased by 20-30% in the last 20 years. However, the absolute risk increase is only 1-4 per 100,000 persons. Screening average risk patients under age 50 should not be encouraged at this time. Evidence: • Population
Cancer prevention with aspirin in hereditary colorectalcancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lynch syndrome is associated with an increased risk of colorectalcancer and with a broader spectrum of cancers, especially endometrial cancer. In 2011, our group reported long-term cancer outcomes (mean follow-up 55·7 months [SD 31·4]) for participants with Lynch syndrome enrolled (...) outcomes were monitored for at least 10 years from recruitment with English, Finnish, and Welsh participants being monitored for up to 20 years. The primary endpoint was development of colorectalcancer. Analysis was by intention to treat and per protocol. The trial is registered with the ISRCTN registry, number ISRCTN59521990.Between January, 1999, and March, 2005, 937 eligible patients with Lynch syndrome, mean age 45 years, commenced treatment, of whom 861 agreed to be randomly assigned
of Digestive, Endocrine, Oncologic and Liver Transplant Surgery, University Hospital, François Rabelais University, Tours, France. 10 Department of Hepatobiliary, Oncologic and Transplant Surgery, AP-HP, Paul Brousse Hospital, Paris-Sud University, Villejuif, France. PMID: 32209911 DOI: Item in Clipboard Full-text links Cite Abstract Objective: To answer whether synchronous colorectalcancer liver metastases (SLM) should be resected simultaneously with primary cancer or should be delayed. Summary (...) background data: Numerous studies have compared both strategies. All were retrospective and conclusions were contradictory. Methods: Adults with colorectalcancer and resectable SLM were randomly assigned to either simultaneous or delayed resection of the metastases. The primary outcome was the rate of major complications within 60 days following surgery. Secondary outcomes included overall and disease-free survival. Results: A total of 105 patients were recruited. Eighty-five patients (39 and 46
Long-Term ColorectalCancer Incidence and Mortality After a Single Negative Screening Colonoscopy. Current guidelines recommend a 10-year interval between screening colonoscopies, but evidence is limited.To assess the long-term risk for colorectalcancer (CRC) and death from CRC after a high- and low-quality single negative screening colonoscopy.Observational study.Polish Colonoscopy Screening Program.Average-risk individuals aged 50 to 66 years who had a single negative colonoscopy (...) (no neoplastic findings).Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) of CRC after high- and low-quality single negative screening colonoscopy. High-quality colonoscopy included a complete examination, with adequate bowel preparation, performed by endoscopists with an adenoma detection rate of 20% or greater.Among 165 887 individuals followed for up to 17.4 years, CRC incidence (0.28 [95% CI, 0.25 to 0.30]) and mortality (0.19 [CI, 0.16 to 0.21]) were 72% and 81% lower
adenomas 5 mm in size. Future studies may clarify whether length- ening the interval beyond 10 years may be possible. A 10- year follow-up after normal colonoscopy is recommended regardless of indication for the colonoscopy, except for in- dividuals at increased risk for CRC, such as those with his- tory of a hereditary CRC syndrome, personal history of in?ammatory boweldisease, personal history of hereditary cancer syndrome, serrated polyposis syndrome, malignant polyp, personal history of CRC (...) is in keeping with their values and preferences. This article does not include recommendations for follow-up for individuals with hereditary CRC syndromes (eg, Lynch syndrome and familial adenomatous polyposis), in?ammatory boweldisease, a personal history of CRC (includingmalignantpolyps),familyhistoryofCRCorcolo- rectal neoplasia, or serrated polyposis syndrome. As such, our recommendations for follow-up after colonoscopy and polypectomy do not apply to these groups except in cases where polyp ?ndings
?brosis,local residual early carcinoma after endoscopic resection, and non-polypoid colorectal dysplasia in patients with in?ammatory boweldisease. 109 The technique of ESD involves an endoscopic knife for cuttingandsubmucosalinjectantforlifting.Aftersubmuco- sal injection, a circumferential incision is performed to isolate the lesion with 3 or 4 mm surrounding normal mu- cosa. The submucosa under the lesion is injected further. With controlled movements under direct view facilitated with the use (...) months to assess for local recurrence and to clear the colon of synchronous lesions. There is a very high prevalence of synchronous disease in patients with lesions 20 mm. In a large EMR referral cohort with lesions 20 mm, patients had an average of 4 additional conventional adenomas; 40% had an additional advanced adenoma; 20% had an additional lesion 20 mm; and 0.8% had a synchronous cancer not detected by the refer- ring physician. Of those referred for removal of a serrated lesion, 30% had
Regional Therapies for ColorectalCancer Liver Metastases Guideline 2-30a A Quality Initiative of the Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario) Regional Therapies for ColorectalCancer Liver Metastases P. Karanicolas, R. Beecroft, R. Cosby, E. David, M. Kalyvas, E. Kennedy, G. Sapisochin, R. Wong, K. Zbuk and the GastrointestinalDisease Site Group Report Date: March 10, 2020 For information about this document, please contact Dr. Paul Karanicolas or Dr. Robert (...) randomization to disease progression. Guideline 2-30a Section 3: Guideline Methods Overview - March 10, 2020 Page 9 Regional Therapies for ColorectalCancer Liver Metastases Section 3: Guideline Methods Overview This section summarizes the methods used to create the guideline. For the systematic review, see Section 4. THE PROGRAM IN EVIDENCE-BASED CARE The PEBC is an initiative of the Ontario provincial cancer system, Ontario Health (Cancer Care Ontario) (OH [CCO]). The PEBC mandate is to improve the lives
emergency colon or rectal cancer surgery. If resection is not possible, then patients should receive palliative care. , Palliative colostomy should be considered in situations of malignantbowel obstruction. In the assessment of general symptoms, clinicians should determine a patient’s performance status and comorbid conditions, as they can influence the ability to receive and predict the benefit from medical treatment. Diagnosis Recommendations on the methods of diagnosis for patients with colorectal (...) biomarker evaluation guideline. - TABLE 3 Recommendations on Symptom Management TABLE 4 Recommendations on Diagnosis TABLE 5 Recommendations on Staging Symptom Management Recommendations for assisting patients with symptoms of advanced colorectalcancer such as pain or bleeding are in . Discussion. More than 1.8 million patients in the world were diagnosed with colorectalcancer (CRC) in 2018. Among all patients with CRC, 20%-30% have metastatic disease from the outset (synchronous primary tumor
because of palliative treatment and new biological treatments for advanced disease. BetterunderstandingofthenaturalhistoryofGIcancershas shown that most of them are preceded by slowly progressing precancerous conditions or lesions, as well as by early invasive stages, therefore providing opportunities for effective inter- ventions. Beyond the classic adenoma–carcinoma sequence for colorectal carcinogenesis, similar pathways based on metaplasia–dysplasia–cancer progression have been shown for upper GI (...) leadtounderuseorpoorresourcingofhealthfacilities involved inprovidingscreeningservices, with consequent failuretofully realizethe potential benefits to patients. Methods In 2017, the European Society of Gastrointestinal Endoscopy (ESGE) Governing Board established a task force (Public Affairs Working Group led by A.S.) to produce a Position Statement concerning the value of endoscopy for screening purposes in GIcancers. The most prevalent digestivecancers (esophageal squamous cellcarcinoma,esophagealadenocarcinoma,gastric carcinoma
comprised of patients undergoing resection for coloniccancer between January 2007 and March 2016 according to the Danish ColorectalCancer Group database. Patients who subsequently underwent IHR were identified in the Danish Ventral Hernia Database, from which information about the priority of the hernia repair and the size of the fascial defect was retrieved.The study included 17,717 patients, of whom 482 (2.7%) underwent subsequent IHR during a median follow-up of 4.7 (interquartile range 2.8-6.9 (...) Incidence of Incisional Hernia Repair After Laparoscopic Compared to Open Resection of ColonicCancer: A Nationwide Analysis of 17,717 Patients It remains unknown whether laparoscopic compared to open surgery translates into fewer incisional hernia repairs (IHR). The objectives of the current study were to compare the long-term incidence of IHR and the size of repaired hernias between patients subjected to laparoscopic or open resection of colonic cancer.This was a nationwide cohort study
surgery for colorectalcancer were divided randomly into three groups: combined general-TAP anaesthesia (TAP group), combined general-thoracic epidural anaesthesia (TEA group) and standard general anaesthesia (GA group). The primary endpoint was duration of hospital stay. Secondary endpoints included gastrointestinal motility, pain scores and plasma levels of cytokines.In total, 180 patients were randomized and 165 completed the trial. The intention-to-treat analysis showed that duration of hospital (...) Randomized clinical trial of continuous transversus abdominis plane block, epidural or patient-controlled analgesia for patients undergoing laparoscopic colorectalcancer surgery The optimal analgesia regimen after laparoscopic colorectalcancer surgery is unclear. The aim of the study was to characterize the beneficial effects of continuous transversus abdominis plane (TAP) blocks initiated before operation on outcomes following laparoscopic colorectalcancer surgery.Patients undergoing
Avapritinib (Ayvakit) - adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) Drug Approval Package: AYVAKIT AYVAKIT " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: AYVAKIT Company: Blueprint Medicines Corporation Application Number: 212608 Approval Date: 01/09/2020 trong> Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF
with early rectal cancer 23 Preoperative treatment for people with rectal cancer 24 Surgery for people with rectal cancer 26 Surgical technique for people with rectal cancer 27 People with locally advanced or recurrent rectal cancer 28 Surgical volumes for rectal cancer operations 29 Preoperative treatment for people with coloncancer 30 Duration of adjuvant chemotherapy for people with colorectalcancer 30 Colonic stents in acute largebowel obstruction 32 Molecular biomarkers to guide systemic anti (...) , and pT4 and/or pN2), performance status, any comorbidities, age and personal preferences. T o find out why the committee made the recommendation on duration of adjuvant chemotherapy for people with colorectalcancer and how it might affect practice, see rationale and impact. Colonic stents in acute largebowel obstruction Colonic stents in acute largebowel obstruction 1.3.15 Consider stenting for people presenting with acute left-sided largebowel obstruction who are to be treated with palliative
infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 2013;73:3499–3510. 29. Brierley J, Gospodarowicz MK, Wittekind C. TNM classification of malignanttumours (8th edition). Oxford, UK: Wiley-Blackwell, 2017. CEff 090120 16 V3 Final Appendix A SNOMED coding Topography Tumour site SNOMED 2/3 code SNOMED CT terminology SNOMED CT code Oesophagus T-62000/T-56000 Entire oesophagus (body structure) 181245004 Stomach T-63000/T-57000 Entire stomach (body structure) 181246003 (...) allows formulation of a definitive management plan but also is used to: • provide accurate and complete data for cancer registration • provide feedback to other clinical specialties, including surgery, radiology and oncology • allow for high-quality clinical audit and research. GISTs are now considered the most common connective tissue tumour of the gastrointestinal (GI) tract. They have been the subject of great interest over the past decade as a much deeper understanding of the underlying molecular